Safety & Interactions

Mebendazole has a familiar non-cancer safety history, but oncology use still needs proper review because doses and combinations may differ substantially from routine anti-parasitic use.

General tolerability

• generally well tolerated in early cancer studies

• most reported side effects have been mild to moderate

• no major high-dose toxicity signal emerged in the early Phase 2a work referenced here

Main practical considerations

• active-treatment combinations should always be reviewed by the treating team

• liver function, full blood count, and overall treatment burden still matter in higher-dose or long-term use

• repurposed-drug use should never be treated as casual self-medication during active cancer therapy

How to interpret interaction evidence

Cell and laboratory findings can identify a possible interaction. They do not confirm the same effect occurs in people.

Read interaction claims alongside human pharmacokinetic and clinical evidence. See Drug Interaction Evidence and CYP Enzymes for the evidence hierarchy and practical questions to ask.

Clinical positioning

Mebendazole is one of the more interesting repurposed-drug candidates precisely because its safety profile is relatively familiar. But that should support supervised exploration, not unsupervised escalation.

Key References

A phase 2a clinical study on the safety and efficacy of mebendazole in cancer
https://www.nature.com/articles/s41598-021-88433-y

A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer
https://clinicaltrials.gov/study/NCT03628079